The short version: TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring peptide involved in actin regulation and cell migration. It is sold as a research-use-only laboratory chemical, not a medication. The FDA placed TB-500 in Category 2 of bulk drug substances that may present significant safety risks in 2023 (the nomination was later withdrawn, and FDA reviewed TB-500 for the 503A bulks list at a July 2026 advisory committee meeting), and the compound is prohibited at all times by WADA. The published research on TB-500 is dominated by preclinical models, with limited human clinical trial data. Alta Peptides publishes lot-specific certificates of analysis for its research-grade TB-500, which is the baseline standard any researcher should expect before ordering.
Search for “what is TB-500” and you will find a range of explanations that either oversimplify the science or blur the line between naturally occurring thymosin beta-4 and the synthetic fragment sold as a research chemical. The two are related but not identical, and the distinction matters for understanding what the research literature actually supports.
This guide explains what TB-500 is, how it differs from full-length thymosin beta-4, what the published research shows, and what documentation to verify before sourcing.
What TB-500 is, chemically
TB-500 is a synthetic peptide fragment corresponding to the actin-binding domain of thymosin beta-4. The full thymosin beta-4 protein is 43 amino acids long and is found in nearly all mammalian cells. Researchers describe thymosin beta-4 as the major actin-sequestering molecule in cells, with roles in cell migration and tissue repair.
The fragment sold as TB-500 is a short synthetic version that retains the actin-binding sequence. It is not the full protein. Researchers should be precise about this distinction, because the published literature on thymosin beta-4 does not automatically apply to the fragment.
A 2024 study in the Journal of Chromatography B measured TB-500 and its metabolites in in-vitro experiments and in rats, and screened them for wound-healing activity in cell models. Work of this kind is preclinical and does not establish effects in humans.
What the research shows
The research on TB-500 is dominated by animal models and in-vitro studies. The compound is studied for its role in cell migration, tissue repair, and inflammation modulation.
Cell migration and actin regulation
A review published in Trends in Molecular Medicine described thymosin beta-4 as an actin-sequestering protein that regulates actin polymerization, which affects cell motility, migration, and differentiation. The peptide is upregulated in response to tissue injury and plays a role in the wound healing process.
Tissue repair in animal models
A 2010 review published in the FASEB Journal mapped the biological activities of thymosin beta-4 to active sites within short peptide sequences. It linked the LKKTETQ sequence, which includes the central actin-binding domain and is the basis of the TB-500 fragment, to angiogenesis, wound healing, and cell migration in experimental models.
Human clinical data
Human clinical trial data for TB-500 is limited. The compound has not been studied in large randomised controlled trials for any indication. This is a limitation that researchers should understand before interpreting the preclinical data.
The Alta Peptides overview of TB-500 summarises the research context and the documentation standards that apply.
Video: What science says about TB-500
This third-party video provides general context on TB-500 research. It is not affiliated with Alta Peptides and is not a substitute for laboratory documentation or the published literature.
The regulatory status of TB-500
TB-500 is not an FDA-approved drug. It has not received authorization from the MHRA, the FDA, or any other national regulatory body for human use. The compound is sold as a research-use-only laboratory chemical.
The FDA previously placed TB-500 in Category 2 of bulk drug substances that may present significant safety risks when used in compounding. The FDA’s stated concerns were a risk of immunogenicity for certain routes of administration, peptide-related impurities, and the absence of any human exposure data.
As of April 2026, the FDA lists TB-500 among the peptides whose Category 2 nominations were withdrawn by the nominators, and TB-500 was on the agenda of the FDA’s Pharmacy Compounding Advisory Committee meeting on July 23, 2026, where it was discussed for possible inclusion on the 503A bulks list. Neither step authorizes compounding or human use.
TB-500 is also prohibited at all times under the World Anti-Doping Agency’s Prohibited List in the class of Peptide Hormones, Growth Factors, Related Substances, and Mimetics (S2). USADA’s sanction announcement for triathlete Anthony McCauley stated that McCauley accepted a four-year period of ineligibility after an investigation found he possessed and used BPC-157 and TB-500, and promoted several prohibited peptides on social media.
How TB-500 compares to BPC-157
TB-500 and BPC-157 are often discussed together because they are both studied for tissue repair applications. The two compounds operate through different mechanisms.
BPC-157 is a synthetic pentadecapeptide derived from human gastric juice protein. It is studied primarily for angiogenic and anti-inflammatory properties in preclinical models. TB-500 is a fragment of thymosin beta-4 and is studied for cell migration and actin regulation.
The Alta Peptides comparison of BPC-157 and TB-500 explains the mechanistic differences and the research contexts in which each compound is studied.
The researcher’s verification checklist
The difference between a defensible purchase and a gamble comes down to documentation.
1. Lot-specific certificate of analysis
A certificate of analysis (COA) is only meaningful if it corresponds to the exact lot you are buying. The COA should list the lot number, the testing laboratory, the report ID, the date the sample was received, and the date the results were published.
The Alta Peptides TB-500 product page lists the current lot documentation alongside the price, with the testing laboratory and report ID visible for cross-referencing.
2. Complete analytical panel
A certificate that lists only “purity: 99%” is incomplete. The useful fields are identity by mass spectrometry, purity by HPLC, measured content, endotoxin, and sterility.
3. Named independent laboratory
The testing laboratory should be identified and should be a different organisation from the supplier. In the UK, UKAS accreditation is the recognised mark of competence for testing laboratories.
4. Research-use-only boundary
The listing should not publish dosing, administration, or human-use content. The Wolverine stack product page is an example of how the company documents a multi-peptide blend that includes TB-500.
How Alta Peptides approaches TB-500 documentation
Alta Peptides is a UK-based research peptide supplier that publishes lot-specific documentation for each product configuration. The company’s certificates page collects the reports for all products so that researchers can compare documentation across configurations.
The TB-500 product page shows the current lot report with the purity, measured content, and identity results visible. The company maintains a research-use-only boundary throughout its product descriptions.
Comparing TB-500 and related compounds
| Compound | Origin | Primary research interest | Evidence level |
|---|---|---|---|
| TB-500 | Fragment of thymosin beta-4 | Cell migration, actin regulation | Preclinical |
| Thymosin beta-4 | Full-length protein | Tissue repair, cell migration | Preclinical and early clinical |
| BPC-157 | Gastric juice protein fragment | Angiogenesis, tissue repair | Preclinical |
| GHK-Cu | Copper-binding tripeptide | Collagen synthesis, matrix remodelling | Moderate for topical use |
Common questions about TB-500
What is TB-500?
TB-500 is a synthetic peptide fragment corresponding to the actin-binding domain of thymosin beta-4, a naturally occurring protein found in nearly all mammalian cells. It is sold as a research-use-only laboratory chemical, not a medication.
Is TB-500 the same as thymosin beta-4?
No. TB-500 is a synthetic fragment of the full thymosin beta-4 protein. The full protein is 43 amino acids long; TB-500 is a shorter synthetic version that retains the actin-binding domain. Researchers should confirm the identity of any product by its COA, not by the name on the vial.
Has TB-500 been studied in human clinical trials?
Human clinical trial data for TB-500 is limited. The compound has been studied primarily in animal models and in-vitro systems. No large randomised controlled trials have been published for any indication.
Is TB-500 prohibited in sport?
Yes. TB-500 is prohibited at all times under the World Anti-Doping Agency’s Prohibited List in the class of Peptide Hormones, Growth Factors, Related Substances, and Mimetics (S2). Athletes subject to anti-doping testing should be aware of the prohibition.
What should a TB-500 COA show?
A complete COA should report identity by mass spectrometry, purity by HPLC with the method stated, measured content or assay value, endotoxin testing, and sterility testing. It should also include the lot number, the testing laboratory’s name, the report ID, and the dates of sample receipt and result reporting.
How do I verify that a COA is real?
Check that the testing laboratory is named and that the report ID can be cross-referenced. Some laboratories publish verification portals where a report ID can be entered to confirm the document’s authenticity.
Important notice: This article is provided for educational and informational purposes only. It does not constitute medical, legal, or regulatory advice. Research peptides discussed here are sold exclusively for laboratory research use and are not approved by the MHRA, the FDA, or any other regulatory agency for human or veterinary use. Nothing in this article should be construed as guidance for human consumption, dosing, or administration. Researchers are responsible for complying with all applicable laws and regulations in their jurisdiction. Always consult the product label, the certificate of analysis, and a qualified professional before making decisions about any substance.